

Clinical trials of omapatrilat

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
omapatrilat vs enalapril			
OVERTURE , 2002 n=2886/2884 follow-up: 14.5 months	omapatrilat 40 mg once daily versus enalapril 10 mg twice daily	patients with NYHA II-IV heart failure	Parallel groups double blind 42 countries
omapatrilat vs lisinopril			
IMPRESS , 2000 n=289/284 follow-up: 12 weeks (24 weeks)	omapatrilat target dose 40 mg daily versus lisinopril target dose 20mg daily	patients with NTHA II-IV congestive heart failure, LEVF <=40% , and receiving ACE inhibitor	Parallel groups double blind USA, canada

└ More details and results :

- vasopeptidase inhibitor for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q243>

References

OVERTURE, 2002:

Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, Swedberg K Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). *Circulation* 2002;106:920-6 [[12186794](#)]

Solomon SD, Skali H, Bourgoun M, Fang J, Ghali JK, Martelet M, Wojciechowski D, Ansmite B, Skards J, Laks T, Henry D, Packer M, Pfeffer MA, , Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. *Am Heart J* 2005;150:257-62. [[16086927](#)] [10.1016/j.ahj.2004.09.056](https://doi.org/10.1016/j.ahj.2004.09.056)

IMPRESS, 2000:

Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, Porter CB, Proulx G, Qian C, Block AJ Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. *Lancet* 2000;356:615-20 [[10968433](#)]

Entry terms: omapatrilat, Vanlev, BMS 186716, BMS-186716,